drugset / Trial / NCT06072326
dApagliflozin SC0062 and Prevention of Renal Injury; a Randomized Evaluation
Phase 2
Not yet recruiting
36 enrolled
University Medical Center Groningen
Biocity Biopharmaceutics Co., Ltd. · collabJuvenile Diabetes Research Foundation · collab
RandomizedCrossoverOpen-labelTreatment
Summary
The aim of this study is to test the hypothesis that dapagliflozin (SGLT2 inhibitor) and SC0062 (ERA) combination therapy augments nephroprotection and mitigates fluid retention and ketogenesis in people with T1D through complementary and synergistic mechanisms of actions.
Timeline
- Start
- 2026-01
- Primary completion
- 2027-12
- Completion
- 2028-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dapagliflozin | Small molecule | 5 mg | — |
| Subject | SC0062 | Unknown | 10 mg | — |